On August 19, Axsome Therapeutics Inc. (NASDAQ:AXSM) stated that it had received a Paragraph IV Certification Notice Letter from Apotex Inc., which had applied with the FDA to produce a generic version of Symbravo. H.C Wainwright states that the pharmaceutical company intends to reply to the notification letter, characterizing this challenge as "normal course of business in the specialty pharmaceuticals arena."